Hospital
Calcasieu Cameron Hospital Service District
Calcasieu Cameron Hospital Service District was paid $12.29M by Medicaid between Jan 2018 and Dec 2024, across 159 billing codes. Its largest line is 99284, emergency room visit (serious) — 30% of everything it billed.
33Billing provider infoCALCASIEU CAMERON HOSPITAL SERVICE DISTRICT
SULPHUR, LA 70663
SULPHUR, LA 70663
33aNPI1093719932assigned 06/09/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.29M
24GClaims385,016
24DCodes billed159
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#32 of 96
Median peer was paid$5.17M
This provider vs. median2.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 46,257 | $1.09M | |
| 2019 | 44,187 | $1.14M | |
| 2020 | 33,150 | $1.08M | |
| 2021 | 55,006 | $1.90M | |
| 2022 | 67,692 | $2.55M | |
| 2023 | 74,818 | $2.57M | |
| 2024incomplete | 63,906 | $1.97M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 22,101 | 19,218 | $3.64M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 27,780 | 24,719 | $2.80M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.5% | 4,027 | 3,375 | $798K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.3% | 1,758 | 1,478 | $652K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.7% | 9,796 | 9,088 | $579K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 1,667 | 1,417 | $316K |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.2% | 508 | 447 | $265K |
| 80053 | Comprehensive metabolic panel | 1.8% | 30,010 | 25,697 | $222K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 4,001 | 3,601 | $219K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.7% | 4,418 | 4,179 | $203K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 4,759 | 4,125 | $198K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 33,249 | 28,417 | $180K |
147 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 5,021 | $144K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 8,451 | $139K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.1% | 5,700 | $130K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 418 | $106K |
| 80061 | Lipid panel | <1% | 8,227 | $95K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,810 | $93K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 260 | $88K |
| 36415 | Collection of venous blood by venipuncture | <1% | 38,966 | $80K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,074 | $69K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,572 | $68K |
| G0378 | Hospital observation service, per hour | <1% | 2,782 | $66K |
| 81001 | <1% | 31,603 | $66K | |
| 93000 | <1% | 2,805 | $60K | |
| 80050 | General health panel | <1% | 1,407 | $57K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,588 | $56K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,069 | $51K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,466 | $48K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,326 | $44K |
| 80081 | <1% | 666 | $43K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,331 | $43K |
| 81025 | <1% | 6,563 | $42K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,995 | $37K |
| 87088 | <1% | 5,844 | $36K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 86 | $34K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,895 | $32K |
| 84484 | <1% | 4,237 | $30K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,271 | $29K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,368 | $25K |
| 76801 | <1% | 453 | $24K | |
| 82553 | <1% | 4,294 | $24K | |
| 87070 | <1% | 3,398 | $24K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,434 | $24K |
| 82550 | <1% | 5,416 | $23K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,633 | $18K |
| 94726 | <1% | 420 | $18K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,145 | $15K |
| 80076 | <1% | 1,975 | $14K | |
| 94060 | <1% | 431 | $12K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 196 | $11K |
| 83690 | <1% | 2,152 | $11K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 34 | $9K |
| 94729 | <1% | 435 | $8K | |
| 0002A | <1% | 196 | $8K | |
| 0001A | <1% | 188 | $7K | |
| 84481 | <1% | 723 | $7K | |
| 83880 | <1% | 322 | $7K | |
| 87653 | <1% | 215 | $7K | |
| J2704 | Injection, propofol, 10 mg | <1% | 6,700 | $7K |
| 59025 | Fetal non-stress test | <1% | 196 | $7K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 240 | $7K |
| 84439 | <1% | 828 | $6K | |
| 74019 | <1% | 254 | $5K | |
| J3410 | Injection, hydroxyzine hcl, up to 25 mg | <1% | 136 | $5K |
| 82728 | <1% | 421 | $4K | |
| 82043 | <1% | 760 | $4K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,166 | $4K |
| 82607 | <1% | 316 | $4K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,662 | $4K |
| 82746 | <1% | 327 | $4K | |
| 86803 | <1% | 308 | $4K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 965 | $3K |
| 86376 | <1% | 273 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,737 | $3K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 70 | $3K |
| 87807 | <1% | 210 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 151 | $2K |
| 94664 | <1% | 409 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 894 | $2K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 78 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 88 | $2K |
| 87077 | <1% | 355 | $2K | |
| 87186 | <1% | 320 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 48 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 631 | $2K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 72 | $2K |
| 83550 | <1% | 293 | $2K | |
| 86780 | <1% | 427 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 288 | $2K |
| 87210 | <1% | 443 | $2K | |
| 94760 | <1% | 1,903 | $2K | |
| 83540 | <1% | 378 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 793 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 84 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 613 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,148 | $1K |
| 87081 | <1% | 215 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 51 | $1K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 26 | $1K |
| 80074 | <1% | 27 | $1K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 401 | $1K |
| 82570 | <1% | 181 | $953.52 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $927.24 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 64 | $866.44 |
| 85045 | <1% | 277 | $864.06 | |
| 73630 | <1% | 39 | $756.79 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 13 | $746.46 |
| 83525 | <1% | 60 | $741.24 | |
| 85379 | <1% | 97 | $713.07 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 13 | $711.40 |
| 85610 | <1% | 238 | $558.50 | |
| 0003A | <1% | 12 | $552.88 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 150 | $465.65 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,296 | $462.93 |
| 87529 | <1% | 15 | $421.08 | |
| 87400 | <1% | 55 | $400.42 | |
| 94761 | <1% | 107 | $396.90 | |
| 85730 | <1% | 133 | $391.48 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 14 | $385.99 |
| 83735 | <1% | 81 | $374.47 | |
| 86140 | <1% | 103 | $352.48 | |
| 86850 | <1% | 613 | $311.02 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 27 | $305.67 |
| 84550 | <1% | 81 | $294.49 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 60 | $259.85 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 26 | $235.94 |
| 82948 | <1% | 65 | $226.62 | |
| 82150 | <1% | 45 | $224.94 | |
| 86696 | <1% | 12 | $212.85 | |
| 83615 | <1% | 53 | $212.64 | |
| 83020 | <1% | 19 | $206.56 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 17 | $201.68 |
| 83605 | <1% | 15 | $173.55 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 12 | $160.08 |
| 86901 | <1% | 633 | $142.16 | |
| 86900 | <1% | 631 | $142.15 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 404 | $136.86 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 526 | $130.42 |
| 84436 | <1% | 29 | $117.20 | |
| 85652 | <1% | 56 | $97.76 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 94 | $89.17 |
| 85007 | <1% | 76 | $79.45 | |
| 82950 | <1% | 12 | $52.25 | |
| 85014 | <1% | 12 | $32.69 | |
| 85018 | <1% | 12 | $32.69 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 345 | $27.65 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 148 | $23.08 |
| 85008 | <1% | 111 | $18.18 | |
| 84703 | <1% | 109 | $15.04 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 109 | $10.66 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 171 | $3.74 |
| 91300 | 0% | 439 | $0.00 | |
| J7342 | Instillation, ciprofloxacin otic suspension, 6 mg | 0% | 24 | $0.00 |
| 00000 | 0% | 361 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 13 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 13 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 30 | $0.00 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJAMES, JOBIE (CHEIF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Calcasieu Cameron Hospital Service District | Sulphur, LA | $906K |
| Calcasieu Cameron Hospital Service District | Sulphur, LA | $658K |
| Calcasieu Cameron Hospital Service District | Sulphur, LA | $430K |
| Calcasieu Cameron Hospital Service District | Cameron, LA | $96K |
| Calcasieu Cameron Hospital Service District | Sulphur, LA | $17K |
| Calcasieu Cameron Hospital Service District | Sulphur, LA | $14K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.